Relevance of reviewing endpoint analysis for negative results on the Xpert Xpress Flu/RSV.
Xpert
endpoint
influenza A
quality control
rapid PCR
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
revised:
02
11
2019
received:
09
08
2019
accepted:
28
03
2020
medline:
7
4
2020
pubmed:
7
4
2020
entrez:
7
4
2020
Statut:
ppublish
Résumé
After the implementation of the Xpert Xpress Flu/respiratory syncytial virus (RSV) assay for rapid respiratory molecular testing, we investigated the significance of reported endpoint values for influenza A, influenza B, and RSV). This study prospectively analyzed nasopharyngeal swabs submitted to our virology laboratory in the 2018/19 influenza season. Initial testing was performed on the Xpress Flu/RSV assay. Samples were further tested on a laboratory-developed multiplex polymerase chain reaction (laboratory-developed multiplex respiratory test [LDT]) if the sample was reported as negative by the Xpress Flu/RSV but had an elevated endpoint value ≥5 for any respiratory virus target. There were 1040 negative results on the Xpress Flu/RSV; thirty-one had at least one endpoint value ≥5 [influenza A (25), influenza B (1), RSV (2), influenza A/RSV (1), and influenza A/B/RSV (2)]. Five samples (5/31, 16.1%) were positive on the LDT for influenza A or RSV. In contrast, the positivity rate on the LDT for negative Xpress Flu/RSV samples with endpoint values less than 5 was 0.35% (P < .0001). A threshold for endpoint values could not reliably be established to differentiate a potential influenza A positive result from a negative result on the LDT. Routine evaluation ofendpoint values should be a consideration for laboratories implementing Xpress Flu/RSV, in addition to supplementary respiratory virus testing for clinically relevant situations.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3839-3842Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Brendish NJ, Malachira AK, Armstrong L, et al. Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial. Lancet Respir Med. 2017;5(5):401-411.
Lowe CF, Leung V, Karakas L, et al. Targeted management of influenza A/B outbreaks incorporating the cobas® Influenza A/B & RSV into the virology laboratory. J Hosp Infect. 2018;101(1):38-41.
Cepheid. Xpert® Xpress Flu/RSV product insert. 2018.
Lowe CF, Payne M, Puddicombe D, et al. Antimicrobial stewardship for hospitalized patients with viral respiratory tract infections. Am J Infect Control. 2017;45(8):872-875.
Petrie JG, Ohmit SE, Cowling BJ, et al. Influenza transmission in a cohort of households with children: 2010-2011. PLoS One. 2013;8(9):2010-2011.
Byington CL, Ampofo K, Stockmann C, et al. Community surveillance of respiratory viruses among families in the Utah better identification of germs-longitudinal viral epidemiology (BIG-LoVE) Study. Clin Infect Dis. 2015;61(8):1217-1224.
Centers for Disease Control and Prevention. Prevention Strategies for Seasonal Influenza in Healthcare Settings. 2018.
Azar MM, Landry ML. Detection of influenza A and B viruses and respiratory syncytial virus by use of Clinical Laboratory Improvement Amendments of 1988 (CLIA)-waived point-of-care assays: a paradigm shift to molecular tests. J Clin Microbiol. 2018;56(7):e00367-18.
Banerjee D, Kanwar N, Hassan F, Essmyer C, Selvarangan R. Comparison of six sample-to-answer influenza A/B and respiratory syncytial virus nucleic acid amplification assays using respiratory specimens from children. J Clin Microbiol. 2018;56(11):e00930-18.
Lifen L, Kaplan SE, Lopez JC, Stiles J, Lu X, Tan Y-W. Parallel validation of three molecular devices for simultaneous detection and identification of influenza a and b and respiratory syncytial viruses. J Clin Microbiol. 2018;56(3):e01691-17.
Ho YII, Wong AH, Lai RWM. Comparison of the cepheid xpert xpress Flu/RSV assay to inhouse Flu/RSV triplex real-time RT-PCR for rapid molecular detection of influenza A, influenza B and respiratory syncytial virus in respiratory specimens. J Med Microbiol. 2018;67(11):1576-1580.